← Back to Screener
Biote Corp. Class A Common Stock (BTMD)
Price$2.24
Favorite Metrics
Price vs S&P 500 (26W)-28.60%
Price vs S&P 500 (4W)35.60%
Market Capitalization$87.80M
P/E Ratio (Annual)3.25x
All Metrics
P/CF (Annual)2.49x
Book Value / Share (Quarterly)$1.29
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.22%
Cash Flow / Share (Quarterly)$0.92
Price vs S&P 500 (YTD)-18.75%
Gross Margin (TTM)71.46%
Net Profit Margin (TTM)14.07%
EPS (TTM)$0.81
10-Day Avg Trading Volume0.34M
EPS Excl Extra (TTM)$0.81
Revenue Growth (5Y)10.51%
EPS (Annual)$0.74
ROI (Annual)79.32%
Gross Margin (Annual)71.46%
Net Profit Margin (5Y Avg)8.05%
Cash / Share (Quarterly)$0.79
P/E Basic Excl Extra (TTM)3.25x
Revenue Growth QoQ (YoY)-6.87%
EPS Growth (5Y)-26.84%
P/E Normalized (Annual)3.25x
ROA (Last FY)25.13%
Revenue Growth TTM (YoY)-2.52%
EBITD / Share (TTM)$1.49
Operating Margin (TTM)18.50%
Cash Flow / Share (Annual)$0.92
P/B Ratio8.21x
P/B Ratio (Quarterly)36.65x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)0.98x
Net Interest Coverage (TTM)4.43x
ROA (TTM)24.20%
EPS Growth QoQ (YoY)-45.31%
EV / EBITDA (TTM)3.74x
EPS Incl Extra (Annual)$0.74
Current Ratio (Annual)1.22x
Quick Ratio (Quarterly)0.71x
3-Month Avg Trading Volume0.22M
52-Week Price Return-32.93%
EV / Free Cash Flow (Annual)6.68x
P/E Incl Extra (TTM)3.25x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.71
P/S Ratio (Annual)0.46x
Asset Turnover (Annual)1.79x
52-Week High$4.75
Operating Margin (5Y Avg)7.54%
EPS Excl Extra (Annual)$0.74
CapEx CAGR (5Y)37.63%
26-Week Price Return-19.86%
Quick Ratio (Annual)0.71x
13-Week Price Return-6.72%
Total Debt / Equity (Annual)9.02x
Current Ratio (Quarterly)1.22x
Enterprise Value$189.212
Revenue / Share Growth (5Y)-17.89%
Asset Turnover (TTM)1.72x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)3.24x
Pretax Margin (Annual)19.55%
Cash / Share (Annual)$0.79
3-Month Return Std Dev74.99%
Gross Margin (5Y Avg)68.53%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)8.97%
ROE (Last FY)795.12%
Net Interest Coverage (Annual)4.43x
EPS Basic Excl Extra (Annual)$0.74
P/FCF (TTM)3.10x
Receivables Turnover (TTM)26.51x
EV / Free Cash Flow (TTM)6.68x
Total Debt / Equity (Quarterly)3.35x
EPS Incl Extra (TTM)$0.81
Receivables Turnover (Annual)26.51x
ROI (TTM)-1.69%
P/S Ratio (TTM)0.46x
Pretax Margin (5Y Avg)8.93%
Revenue / Share (Annual)$5.24
Tangible BV / Share (Annual)$-5.13
Forward P/E7.72x
Free OCF CAGR (5Y)2.50%
Price vs S&P 500 (52W)-68.03%
P/E Ratio (TTM)3.25x
EPS Growth TTM (YoY)3772.86%
Year-to-Date Return-14.62%
5-Day Price Return24.02%
EPS Normalized (Annual)$0.74
ROA (5Y Avg)17.80%
Net Profit Margin (Annual)14.07%
Month-to-Date Return64.44%
Cash Flow / Share (TTM)$0.00
EBITD / Share (Annual)$1.38
EPS Growth (3Y)-71.38%
Operating Margin (Annual)18.50%
LT Debt / Equity (Annual)7.80x
P/CF (TTM)2.49x
P/E Excl Extra (TTM)3.25x
LT Debt / Equity (Quarterly)2.88x
EPS Basic Excl Extra (TTM)$0.81
P/TBV (Quarterly)66.46x
Inventory Turnover (TTM)3.24x
Pretax Margin (TTM)19.55%
Book Value / Share (Annual)$-4.60
Price vs S&P 500 (13W)-9.59%
Net Margin Growth (5Y)-10.89%
Beta1.67x
P/FCF (Annual)3.10x
Revenue / Share (TTM)$5.33
ROE (TTM)-1.60%
52-Week Low$1.27
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceutical Preparations(15)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BTMDBiote Corp. Class A Common Stock | 0.46x | -2.52% | 71.46% | -26.84% | $2.24 |
CRONCronos Group Inc. Common Share | 6.99x | 24.63% | 42.81% | -49.98% | $2.76 |
TLRYTilray Brands, Inc. Common Stock | 0.97x | 3.82% | 27.68% | — | $7.15 |
CGCCanopy Growth Corporation Common Shares | 2.55x | 0.59% | 26.56% | — | $1.20 |
NAGENiagen Bioscience, Inc. Common Stock | 3.01x | 29.95% | 64.28% | — | $4.87 |
USNAUSANA Health Sciences Inc | 0.41x | 5.88% | 78.29% | -37.04% | $20.64 |
SNDLSundial Growers Inc. Common Shares | 0.58x | 2.82% | 27.33% | — | $1.54 |
MDWDMediWound Ltd. | 13.35x | -16.14% | 19.19% | — | $17.35 |
ACBAurora Cannabis Inc. Common Shares | 0.77x | 16.54% | 1.35% | — | $3.72 |
FTLFFitLife Brands, Inc. Common Stock | 1.29x | 1.34% | 37.58% | -20.04% | $8.99 |
NAIINatural Alternatives International Inc. | 0.13x | 10.92% | 9.06% | — | $2.76 |
About
Biote Corp provides hormone optimization solutions and operational support to licensed practitioners. The company supplies practitioners with products and tools to offer personalized hormone therapy programs to patients. Biote generates revenue through operations in the United States and international markets.